FRET Assays for the Identification of

FRET HSP90 Sba1 accuracy assessment of Kd cancer drug discovery fungal infections high-throughput screening (HTS) capability p23

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
17 Apr 2024
Historique:
received: 03 03 2024
revised: 11 04 2024
accepted: 12 04 2024
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 27 4 2024
Statut: epublish

Résumé

Heat shock protein 90 (HSP90) is a critical target for anticancer and anti-fungal-infection therapies due to its central role as a molecular chaperone involved in protein folding and activation. In this study, we developed

Identifiants

DOI: 10.3390/ph17040516 PMID: 38675476
pubmed: 38675476
pii: ph17040516
doi: 10.3390/ph17040516
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Philip Kohlmann (P)

Institute of Pharmaceutical and Medicinal Chemistry, Pharmacampus, University of Münster, 48149 Münster, Germany.

Sergey N Krylov (SN)

Department of Chemistry, York University, Toronto, ON M3J 1P3, Canada.
Centre for Research on Biomolecular Interactions, York University, Toronto, ON M3J 1P3, Canada.

Pascal Marchand (P)

Cibles et Médicaments des Infections et de l'Immunité, IICiMed, Nantes Université, UR 1155, F-44000 Nantes, France.
ORCID: 0000-0001-7773-8642

Joachim Jose (J)

Institute of Pharmaceutical and Medicinal Chemistry, Pharmacampus, University of Münster, 48149 Münster, Germany.
ORCID: 0000-0002-0666-2676

Classifications MeSH